US EditionPublished • loading... • Updated
Fosun Pharma-Funded Biotech Licenses Insilico’s NLRP3 Inhibitor
- Insilico Medicine and Hygtia Therapeutics have formed a global strategic collaboration to co-develop ISM8969, a novel NLRP3 inhibitor for CNS diseases treatment.
- Insilico is eligible to receive payments totaling up to USD$66 million, including an upfront payment of USD$10 million expected within 30 days.
- Insilico will lead the initial clinical development and submit an IND for ISM8969 in a Phase 1 clinical trial for Parkinson's disease.
- Hygtia Therapeutics will take charge of future global clinical studies and commercialization efforts for ISM8969.
Insights by Ground AI
47 Articles
47 Articles
Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment
Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and Insilico is eligible to receive up to USD 66 million in upfront and milestone payments. Insilico will lead the IND submission and Phase 1 clinical trial of ISM8…
·New York, United States
Read Full Article
Fosun Pharma-funded biotech licenses Insilico’s NLRP3 inhibitor
A biotech funded by Shanghai Fosun Pharmaceutical is licensing a preclinical asset developed by Insilico Medicine in the NLRP3 space, which has garnered industry interest in recent months. Hygtia Therapeutics will get half the global ...
Coverage Details
Total News Sources47
Leaning Left5Leaning Right5Center18Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 18%
C 64%
R 18%
Factuality
To view factuality data please Upgrade to Premium
